

- Pedro-Botet, J., Schaefer, E. J., Bakker-Arkema, R. G., Black, D. M., Stein, E. M., Corella, D., & Ordovas, J. M. (2001). Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. *Atherosclerosis*, 158(1), 183-193.
- Pi-Sunyer, F. X. (2009). The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. *Postgraduate medicine*, 121(5), 94.
- Poli, A. (2007). Atorvastatin. *Drugs*, 67(1), 3-15.
- Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., & Davies, M. (2010). Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *The Lancet*, 375(9724), 1447-1456.
- Psaty, B. M., Smith, N. L., Siscovick, D. S., Koepsell, T. D., Weiss, N. S., Heckbert, S. R., & Furberg, C. D. (1997). Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. *Jama*, 277(9), 739-745.
- Reddy, P., Greaves, C., Dunbar, J., & Schwarz, J. (2010). Diabetes prevention in practice. P. Schwarz (Ed.). Tumaini-Inst. für Präventionsmanagement.
- Redon, J., Olsen, M. H., Cooper, R. S., Zurriaga, O., Martinez-Beneito, M. A., Laurent, S., & Mancia, G. (2011). Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. *European heart journal*, 32(11), 1424-1431.